These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 39310106

  • 1. Honokiol enhances the sensitivity of cetuximab in KRASG13D mutant colorectal cancer through destroying SNX3-retromer complex.
    Zhu Q, Zhang R, Gu X, Zhao Z, Gao Q, Chen M, Wu Q, Xie T, Sui X.
    Theranostics; 2024; 14(14):5443-5460. PubMed ID: 39310106
    [Abstract] [Full Text] [Related]

  • 2. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
    Chu YC, Tsai TY, Yadav VK, Deng L, Huang CC, Tzeng YM, Yeh CT, Chen MY.
    Int J Mol Sci; 2021 Jul 14; 22(14):. PubMed ID: 34299137
    [Abstract] [Full Text] [Related]

  • 3. Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.
    Chen P, Li X, Zhang R, Liu S, Xiang Y, Zhang M, Chen X, Pan T, Yan L, Feng J, Duan T, Wang D, Chen B, Jin T, Wang W, Chen L, Huang X, Zhang W, Sun Y, Li G, Kong L, Chen X, Li Y, Yang Z, Zhang Q, Zhuo L, Sui X, Xie T.
    Theranostics; 2020 Jul 14; 10(11):5107-5119. PubMed ID: 32308771
    [Abstract] [Full Text] [Related]

  • 4. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF, Iida M, Myers RA, Campbell DA, Hintz KA, Armstrong EA, Li C, Wheeler DL.
    Oncogene; 2011 Feb 03; 30(5):561-74. PubMed ID: 20956938
    [Abstract] [Full Text] [Related]

  • 5. Dynamic alterations of genome and transcriptome in KRAS G13D mutant CRC PDX model treated with cetuximab.
    Zhang H, Yuan L, Liu L, Yan C, Cheng J, Fu Q, Tong Z, Jiang W, Zheng Y, Zhao P, Zhang G, Fang W.
    BMC Cancer; 2020 May 13; 20(1):416. PubMed ID: 32404198
    [Abstract] [Full Text] [Related]

  • 6. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations.
    Lee J, Lee I, Han B, Park JO, Jang J, Park C, Kang WK.
    J Natl Cancer Inst; 2011 Apr 20; 103(8):674-88. PubMed ID: 21398618
    [Abstract] [Full Text] [Related]

  • 7. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/AKT and PDGFRβ/AKT signaling pathways.
    Liu YF, Feng ZQ, Chu TH, Yi B, Liu J, Yu H, Xue J, Wang YJ, Zhang CZ.
    Phytomedicine; 2024 Apr 20; 126():155462. PubMed ID: 38394734
    [Abstract] [Full Text] [Related]

  • 8. AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer.
    Ye H, Liu Y, Wu K, Luo H, Cui L.
    Cell Commun Signal; 2020 Jul 23; 18(1):115. PubMed ID: 32703218
    [Abstract] [Full Text] [Related]

  • 9. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy.
    McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC.
    Sci Signal; 2019 Sep 24; 12(600):. PubMed ID: 31551296
    [Abstract] [Full Text] [Related]

  • 10. Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation.
    Ohishi T, Kato Y, Kaneko MK, Ohba SI, Inoue H, Harakawa A, Kawada M.
    Int J Mol Sci; 2020 Aug 21; 21(17):. PubMed ID: 32839411
    [Abstract] [Full Text] [Related]

  • 11. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
    De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, Lamba S, Arena S, Frattini M, Piessevaux H, Van Cutsem E, O'Callaghan CJ, Khambata-Ford S, Zalcberg JR, Simes J, Karapetis CS, Bardelli A, Tejpar S.
    JAMA; 2010 Oct 27; 304(16):1812-20. PubMed ID: 20978259
    [Abstract] [Full Text] [Related]

  • 12. Effects of PHA-665752 and Cetuximab Combination Treatment on In Vitro and Murine Xenograft Growth of Human Colorectal Cancer Cells with KRAS or BRAF Mutations.
    Jia YT, Yang DH, Zhao Z, Bi XH, Han WH, Feng B, Zhi J, Gu B, Duan Z, Wu JH, Ju YC, Wang MX, Li ZX.
    Curr Cancer Drug Targets; 2018 Oct 27; 18(3):278-286. PubMed ID: 28359236
    [Abstract] [Full Text] [Related]

  • 13. CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.
    Arriga R, Caratelli S, Lanzilli G, Ottaviani A, Cenciarelli C, Sconocchia T, Spagnoli GC, Iezzi G, Roselli M, Lauro D, Coppola A, Dotti G, Ferrone S, Sconocchia G.
    Int J Cancer; 2020 May 01; 146(9):2531-2538. PubMed ID: 31396956
    [Abstract] [Full Text] [Related]

  • 14. Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines.
    Kim S, Kim N, Kang K, Kim W, Won J, Cho J.
    Cells; 2019 Aug 12; 8(8):. PubMed ID: 31409052
    [Abstract] [Full Text] [Related]

  • 15. Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.
    Koyama M, Kitazawa M, Nakamura S, Matsumura T, Miyazaki S, Miyagawa Y, Muranaka F, Tokumaru S, Okumura M, Yamamoto Y, Ehara T, Hondo N, Takahata S, Takeoka M, Miyagawa SI, Soejima Y.
    Int J Oncol; 2020 Nov 12; 57(5):1179-1191. PubMed ID: 32901840
    [Abstract] [Full Text] [Related]

  • 16. Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9.
    E J, Xing J, Gong H, He J, Zhang W.
    Tumour Biol; 2015 Feb 12; 36(2):1091-7. PubMed ID: 25326806
    [Abstract] [Full Text] [Related]

  • 17. A small molecule approach to degrade RAS with EGFR repression is a potential therapy for KRAS mutation-driven colorectal cancer resistance to cetuximab.
    Lee SK, Cho YH, Cha PH, Yoon JS, Ro EJ, Jeong WJ, Park J, Kim H, Il Kim T, Min DS, Han G, Choi KY.
    Exp Mol Med; 2018 Nov 20; 50(11):1-12. PubMed ID: 30459318
    [Abstract] [Full Text] [Related]

  • 18. A set of defined oncogenic mutation alleles seems to better predict the response to cetuximab in CRC patient-derived xenograft than KRAS 12/13 mutations.
    Chen D, Huang X, Cai J, Guo S, Qian W, Wery JP, Li QX.
    Oncotarget; 2015 Dec 01; 6(38):40815-21. PubMed ID: 26512781
    [Abstract] [Full Text] [Related]

  • 19. Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status.
    Kato J, Futamura M, Kanematsu M, Gaowa S, Mori R, Tanahashi T, Matsuhashi N, Yoshida K.
    Int J Cancer; 2016 Mar 15; 138(6):1516-27. PubMed ID: 26437179
    [Abstract] [Full Text] [Related]

  • 20. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer.
    Yang J, Mo J, Dai J, Ye C, Cen W, Zheng X, Jiang L, Ye L.
    Cell Death Dis; 2021 Nov 13; 12(11):1079. PubMed ID: 34775496
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.